SAVA Cassava Sciences, Inc. Stock Quote

SAVA [NASD]

Index	-	P/E	-	EPS (ttm)	-0.28	Insider Own	5.20%	Shs Outstand	37.72M	Perf Week	12.13%
Market Cap	2.61B	Forward P/E	-	EPS next Y	-0.72	Insider Trans	0.00%	Shs Float	37.41M	Perf Month	100.61%
Income	-8.70M	PEG	-	EPS next Q	-0.12	Inst Own	27.50%	Short Float	10.10%	Perf Quarter	43.79%
Sales	-	P/S	-	EPS this Y	8.80%	Inst Trans	6.59%	Short Ratio	1.99	Perf Half Y	884.29%
Book/sh	7.45	P/B	10.17	EPS next Y	-820.00%	ROA	-8.10%	Target Price	77.80	Perf Year	3031.82%
Cash/sh	8.18	P/C	9.26	EPS next 5Y	-	ROE	-8.30%	52W Range	2.28 - 117.54	Perf YTD	1011.29%
Dividend	-	P/FCF	-	EPS past 5Y	35.40%	ROI	-	52W High	-37.62%	Beta	1.10
Dividend %	-	Quick Ratio	107.10	Sales past 5Y	-	Gross Margin	-	52W Low	3115.64%	ATR	5.96
Employees	11	Current Ratio	107.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	72.73	Volatility	12.07% 10.68%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-99.00%	Profit Margin	-	Rel Volume	0.75	Prev Close	75.79
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Apr 21 BMO	Payout	-	Avg Volume	1.90M	Price	73.32
Recom	2.00	SMA20	26.35%	SMA50	55.42%	SMA200	164.94%	Volume	1,038,441	Change	-3.26%

Apr-27-21

Initiated

B. Riley Securities

Buy

$78

Feb-16-21

Reiterated

H.C. Wainwright

Buy

$20 → $66

Oct-23-20

Initiated

Cantor Fitzgerald

Overweight

$24

Sep-23-20

Upgrade

H.C. Wainwright

Neutral → Buy

$20

May-18-20

Downgrade

H.C. Wainwright

Buy → Neutral

May-15-20

Downgrade

Maxim Group

Buy → Hold

Jan-10-20

Reiterated

Maxim Group

Buy

$3 → $12

Jun-14-21 08:30AM	Cassava Sciences Announces the Appointment of Richard J. Barry to its Board of Directors GlobeNewswire
Jun-12-21 09:15AM	S&P Sets Another Record in Slow Summer Session Zacks
Jun-11-21 06:45AM	Ignore Biogen: 3 Reasons These Stocks Will Be Better Alzheimer's Investments Motley Fool +16.05%
Jun-09-21 08:28AM	Urban Outfitters, Travelzoo, Eli Lilly, Cassava Sciences and Annovis Bio highlighted as Zacks Bull and Bear of the Day Zacks
Jun-08-21 03:16PM	Top Biotech Stocks for Q3 2021 Investopedia
10:09AM	3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug Zacks
Jun-07-21 02:00PM	Why Cassava Sciences Was Up 15% in May Motley Fool +5.35%
01:48PM	Forget Biogen: These 2 Alzheimer's Drug Stocks Could Make You Rich Motley Fool
May-29-21 03:49PM	Top Small-Cap Stocks for June 2021 Investopedia
May-25-21 07:50AM	Are Options Traders Betting on a Big Move in Cassava Sciences (SAVA) Stock? Zacks
May-24-21 08:30AM	Cassava Sciences to Participate in Q&A Panel Discussion on Alzheimers Disease GlobeNewswire
May-21-21 04:10PM	Annoviss 127% Surge Showcases Alzheimers Drug Enthusiasm Bloomberg
04:05PM	Annovis Bio Stock Doubles As Alzheimer's Drug Tops Biogen, Cassava Sciences Investor's Business Daily
May-18-21 12:30PM	Could This Be The Hottest Investment Sector For 2021? Oilprice.com +6.47%
May-12-21 02:15PM	Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development Benzinga
07:30AM	Cassava Sciences Announces New $2.7 Million Research Grant Award from National Institutes of Health GlobeNewswire
May-10-21 03:57PM	Biden's Budget May Boost These 3 Biotechs Motley Fool -6.78%
08:30AM	Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimers disease GlobeNewswire
Apr-27-21 01:08PM	Cassava: Breaking Down B. Rileys New Bullish Call TipRanks +6.05%
08:30AM	Cassava Sciences Invited to Participate in B. Riley Securities Neuroscience Conference GlobeNewswire
Apr-26-21 08:30AM	Cassava Sciences Invited by the NIH to Participate in Sachs 4th Annual Neuroscience Innovation Forum GlobeNewswire +5.61%
Apr-22-21 10:26PM	Cassava Sciences Stock at $110 a Share? This Analyst Thinks Its Possible TipRanks
Apr-21-21 08:30AM	Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release GlobeNewswire +8.46%
Apr-16-21 05:50PM	Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know Zacks
Apr-07-21 06:06AM	5 Ultra-Popular Stocks to Avoid Like the Plague in April Motley Fool
Mar-24-21 11:30AM	Has Cassava Sciences (SAVA) Outpaced Other Medical Stocks This Year? Zacks -6.83%
Mar-23-21 08:30AM	Cassava Sciences Announces Full-year 2020 Financial Results and Business Highlights GlobeNewswire -6.13%
Mar-21-21 06:18AM	Should You Buy Cassava Sciences Stock Now? Motley Fool
Mar-19-21 08:34PM	Cassava: A Promising Yet Risky Alzheimers Pure Play TipRanks
11:38AM	7 High-Flying Stocks That Could Crash 20% or Even More InvestorPlace
Mar-18-21 06:16AM	3 Biotech Stocks to Avoid Right Now Motley Fool -10.03%
Mar-17-21 03:37PM	Why Cassava Sciences Stock Is Skyrocketing Today Motley Fool +19.86%
Mar-15-21 07:02AM	The Zacks Analyst Blog Highlights: Denbury, Riot Blockchain, Marathon Digital Holdings, Silvergate Capital and Cassava Sciences Zacks
Mar-12-21 08:25AM	A Year Into the COVID-19 Pandemic: 5 Stock Winners Zacks
Mar-10-21 09:14AM	Cassava Sciences (SAVA) Up More Than 600% YTD: Here's Why Zacks
Mar-09-21 09:00AM	Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam GlobeNewswire +15.62%
Mar-08-21 11:30AM	Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year? Zacks
11:00AM	Why Cassava Sciences Stock Skyrocketed 145.1% in February Motley Fool
08:30AM	Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-06-21 06:44AM	Could Cassava Sciences Be a Millionaire-Maker Stock? Motley Fool
Feb-26-21 06:01PM	Cassava: Alzheimer Treatments Progress Merits a New Price Target TipRanks
09:47AM	Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid Zacks
08:40AM	Implied Volatility Surging for Cassava Sciences (SAVA) Stock Options Zacks
Feb-23-21 08:30AM	Cassava Sciences to Present at SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-22-21 12:19PM	Cassava Sciences To Start Two Pivotal Trials With Simufilam In Alzheimer's Benzinga
08:30AM	Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimers Disease GlobeNewswire
Feb-18-21 07:25PM	Cassava: Potential Alzheimers Treatment Opens Door for Lucrative Licensing Deal TipRanks
Feb-16-21 04:16PM	Cassava Stock Pops Again; Can It Take On Biogen In Alzheimer's Drugs? Investor's Business Daily +12.38%
Feb-15-21 05:35AM	Cassava Sciences, Inc. (NASDAQ:SAVA) Insiders Increased Their Holdings Simply Wall St.
Feb-13-21 06:06AM	5 Stocks That Turned $250,000 Into $1 Million (or More) in 1 Month Motley Fool
Feb-12-21 07:00PM	Treating the Causes, Not Symptoms, of Alzheimers Barrons.com
05:08PM	Cassava Sciences Announces Closing of $200 Million Registered Direct Offering GlobeNewswire
Feb-11-21 11:00AM	Could Cassava Sciences Be a Millionaire-Maker Stock? Motley Fool
Feb-10-21 11:40AM	Why Cassava Sciences and Ocugen Stock Fell With the Nasdaq Motley Fool -14.37%
07:51AM	Cassava Sciences Seeks $200M From Equity Offering At 15% Discount To Fund Development Of Lead Candidate Benzinga
07:26AM	Cassava Sciences to offer $200 million of shares priced at $49 each vs. $57.56 at Tuesday's close MarketWatch
06:15AM	Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock GlobeNewswire
Feb-09-21 09:39AM	Cassava (SAVA) Rises on Late-Stage Alzheimer's Study Plans Zacks -5.13%
06:27AM	Should You Sell Cassava Sciences Stock Now? Motley Fool
Feb-08-21 01:20PM	Why Ocugen and Cassava Sciences Stock Led the Nasdaq to All-Time Highs Motley Fool +35.42%
08:56AM	Cassava's stock jumps 18% on plans to initiate late-stage study for Alzheimer's drug MarketWatch
08:30AM	Cassava Sciences Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Clinical Program in Alzheimers Disease GlobeNewswire
08:22AM	What to Know Before Buying Cassava Sciences, the Hot Alzheimers Stock Barrons.com
05:21AM	Cassava Jumps on Plan for Phase 3 Trial of Alzheimer's Drug TheStreet.com
Feb-05-21 11:29AM	Biotech Surpasses GameStop as Best-Performing Retail Pick Bloomberg -29.37%
10:36AM	Cassava: Alzheimers Study Results Are Promising but Its Early Days, Says Analyst TipRanks
Feb-04-21 04:39PM	Cassava Plummets After Three-Day Run On Promising Alzheimer's Drug Investor's Business Daily -27.88%
09:48AM	Dow Jones Today Leads Stocks Higher Amid EBay, PayPal Earnings, Stimulus Progress, Apple EV Buzz Investor's Business Daily
06:42AM	Can This Maverick Biotech Become the Frontrunner in the Fight Against Alzheimer's? Motley Fool
Feb-03-21 06:40PM	Biotech Bonanza: COVID Launches Science at Warp Speed Zacks +58.64%
04:47PM	Cannabis Stocks Pop on News of Jazz-GW Merger Investopedia
10:25AM	Biotech Stock Roundup: AMGN, VRTX Q4 Results, SAVA's Encouraging Drug Data & More Zacks
09:19AM	Cassava Shares Go Through The Roof On Alzheimer Drug Trial Results SmarterAnalyst
09:17AM	Cassava (SAVA) Soars on Encouraging Alzheimer's Study Data Zacks
Feb-02-21 05:49PM	Why Cassava Sciences Stock Skyrocketed Today Motley Fool +141.15%
01:32PM	Cassava Sciences stock nearly triples toward a 10-year high after upbeat data on Alzheimer's treatment MarketWatch
08:30AM	Cassava Sciences Simufilam Improves Cognition and Behavior in Alzheimers Disease in Interim Analysis of Open-label Study GlobeNewswire
07:59AM	Cassava Sciences Doubles on Progress With Alzheimer's Treatment TheStreet.com
Jan-23-21 07:01AM	The 3 Best Healthcare Stocks to Buy for 2021 Motley Fool
Jan-04-21 08:30AM	Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer GlobeNewswire
Dec-22-20 07:31AM	Cassava Sciences' (SAVA) Shares March Higher, Can It Continue? Zacks
Dec-07-20 08:19PM	Is SAVA A Good Stock To Buy Now? Insider Monkey
Nov-27-20 08:30AM	USAN Modifies Lead Drug Candidates Chemical Name to Simufilam GlobeNewswire
Nov-19-20 10:08AM	Pacira (PCRX) Gets European Commission Approval for Exparel Zacks
Nov-18-20 09:36AM	3 Best Biotech Stocks to Buy in November Motley Fool -5.91%
Nov-16-20 10:06AM	Aerie (AERI) Gets Positive CHMP Opinion for Roclanda in EU Zacks
Nov-13-20 09:42AM	Zoetis (ZTS) Librela Gets Marketing Authorization in Europe Zacks -25.13%
09:08AM	Cassava Sciences Announces Pricing of $75 Million Public Offering of Common Stock GlobeNewswire
08:07AM	Why Cassava Sciences Stock Is Retreating Today Motley Fool
Nov-12-20 04:48PM	Cassava Sciences Announces Proposed Public Offering of Common Stock GlobeNewswire
Nov-09-20 08:15AM	Cassava Sciences Reports Third Quarter 2020 Financial Results GlobeNewswire -5.05%
Nov-04-20 08:15AM	Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimers Disease GlobeNewswire +25.57%
Oct-26-20 09:19AM	What's in the Cards for Cassava (SAVA) This Earnings Season? Zacks
Oct-23-20 10:15AM	Why Cassava Sciences Is Bolting Higher Today Motley Fool +5.55%
Oct-12-20 03:29PM	We're Not Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Simply Wall St.
Oct-07-20 09:35AM	Why Cassava Sciences Stock Crushed It in September Motley Fool +6.87%
07:05AM	Moving Average Crossover Alert: Cassava Sciences Zacks
Sep-30-20 08:30AM	Cassava Sciences Phase 2b Clinical Results in Alzheimers Selected as Late-Breaking News at CTAD 2020 GlobeNewswire
07:55AM	4 Small Drug Stocks to Look Out For Amid Coronavirus Uncertainty Zacks
Sep-28-20 07:44PM	Cassava Sciences (SAVA) Stock Is up 255% This Month. How Much Higher Can It Go? TipRanks

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BARBIER REMI	President and CEO	May 27	Option Exercise	53.55	56,030	3,000,406	1,134,885	May 28 04:01 PM
ROBERTSON SANFORD	Director	Mar 30	Option Exercise	40.89	7,472	305,521	920,095	Mar 31 09:14 PM
FRIEDMANN NADAV	Chief Medical Officer	Mar 17	Option Exercise	53.55	28,015	1,500,203	92,428	Mar 18 04:06 PM
O DONNELL MICHAEL J	Director	Mar 16	Option Exercise	49.00	4,669	228,781	9,257	Mar 18 03:59 PM
BARBIER REMI	President and CEO	Sep 24	Buy	9.59	10,000	95,900	1,078,855	Sep 24 04:49 PM
ROBERTSON SANFORD	Director	Sep 18	Buy	8.92	36,281	323,627	912,623	Sep 21 04:01 PM
Schoen Eric	Chief Financial Officer	Sep 17	Buy	7.04	2,000	14,080	27,300	Sep 17 05:25 PM
Schoen Eric	Chief Financial Officer	Sep 17	Buy	7.03	10,000	70,300	25,300	Sep 17 05:25 PM
ROBERTSON SANFORD	Director	Sep 17	Buy	6.98	213,719	1,491,759	876,342	Sep 17 05:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience